Literature DB >> 25883796

Virulence genes in a probiotic E. coli product with a recorded long history of safe use.

Trudy M Wassenaar, Anke Zschüttig, Claudia Beimfohr, Thomas Geske, Christian Auerbach, Helen Cook, Kurt Zimmermann, Florian Gunzer.   

Abstract

The probiotic product Symbioflor2 (DSM 17252) is a bacterial concentrate of six different Escherichia coli genotypes, whose complete genome sequences are compared here, between each other as well as to other E. coli genomes. The genome sequences of Symbioflor2 E. coli components contained a number of virulence-associated genes. Their presence seems to be in conflict with a recorded history of safe use, and with the observed low frequency of adverse effects over a period of more than 6 years. The genome sequences were used to identify unique sequences for each component, for which strain-specific hybridization probes were designed. A colonization study was conducted whereby five volunteers were exposed to an exceptionally high single dose. The results showed that the probiotic E. coli could be detected for 3 months or longer in their stools, and this was in particular the case for those components containing higher numbers of virulence-associated genes. Adverse effects from this long-term colonization were absent. Thus, the presence of the identified virulence genes does not result in a pathogenic phenotype in the genetic background of these probiotic E. coli.

Entities:  

Keywords:  Escherichia coli; colonization fitness; genome sequence; probiotic; virulence

Year:  2015        PMID: 25883796      PMCID: PMC4397850          DOI: 10.1556/EUJMI-D-14-00039

Source DB:  PubMed          Journal:  Eur J Microbiol Immunol (Bp)        ISSN: 2062-509X


  20 in total

1.  The sigA gene which is borne on the she pathogenicity island of Shigella flexneri 2a encodes an exported cytopathic protease involved in intestinal fluid accumulation.

Authors:  K Al-Hasani; I R Henderson; H Sakellaris; K Rajakumar; T Grant; J P Nataro; R Robins-Browne; B Adler
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

2.  Functional genomics of probiotic Escherichia coli Nissle 1917 and 83972, and UPEC strain CFT073: comparison of transcriptomes, growth and biofilm formation.

Authors:  Viktoria Hancock; Rebecca Munk Vejborg; Per Klemm
Journal:  Mol Genet Genomics       Date:  2010-10-01       Impact factor: 3.291

3.  Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms.

Authors:  M C Maiden; J A Bygraves; E Feil; G Morelli; J E Russell; R Urwin; Q Zhang; J Zhou; K Zurth; D A Caugant; I M Feavers; M Achtman; B G Spratt
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

4.  Characterization of cellulose production in Escherichia coli Nissle 1917 and its biological consequences.

Authors:  Cláudia Monteiro; Inder Saxena; Xiaoda Wang; Abdul Kader; Werner Bokranz; Roger Simm; David Nobles; Milan Chromek; Annelie Brauner; R Malcolm Brown; Ute Römling
Journal:  Environ Microbiol       Date:  2009-01-23       Impact factor: 5.491

5.  Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917.

Authors:  Lubomir Grozdanov; Carsten Raasch; Jürgen Schulze; Ulrich Sonnenborn; Gerhard Gottschalk; Jörg Hacker; Ulrich Dobrindt
Journal:  J Bacteriol       Date:  2004-08       Impact factor: 3.490

Review 6.  Comparison of 61 sequenced Escherichia coli genomes.

Authors:  Oksana Lukjancenko; Trudy M Wassenaar; David W Ussery
Journal:  Microb Ecol       Date:  2010-07-11       Impact factor: 4.552

7.  VFDB 2012 update: toward the genetic diversity and molecular evolution of bacterial virulence factors.

Authors:  Lihong Chen; Zhaohui Xiong; Lilian Sun; Jian Yang; Qi Jin
Journal:  Nucleic Acids Res       Date:  2011-11-08       Impact factor: 16.971

8.  Identification and characterization of microcin S, a new antibacterial peptide produced by probiotic Escherichia coli G3/10.

Authors:  Anke Zschüttig; Kurt Zimmermann; Jochen Blom; Alexander Goesmann; Christoph Pöhlmann; Florian Gunzer
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

9.  CMG-biotools, a free workbench for basic comparative microbial genomics.

Authors:  Tammi Vesth; Karin Lagesen; Öncel Acar; David Ussery
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

10.  Characterization of probiotic Escherichia coli isolates with a novel pan-genome microarray.

Authors:  Hanni Willenbrock; Peter F Hallin; Trudy M Wassenaar; David W Ussery
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

View more
  13 in total

1.  Safety Evaluation and Colonisation Abilities of Four Lactic Acid Bacteria as Future Probiotics.

Authors:  Ziyanda C Dlamini; Rashwahla L S Langa; Olayinka A Aiyegoro; Anthony I Okoh
Journal:  Probiotics Antimicrob Proteins       Date:  2019-06       Impact factor: 4.609

2.  Campylobacter jejuni increases flagellar expression and adhesion of noninvasive Escherichia coli: effects on enterocytic Toll-like receptor 4 and CXCL-8 expression.

Authors:  Kristen L Reti; Lisa D Tymensen; Shevaun P Davis; Matthias W Amrein; Andre G Buret
Journal:  Infect Immun       Date:  2015-09-14       Impact factor: 3.441

3.  The prediction of virulence based on presence of virulence genes in E. coli may not always be accurate.

Authors:  Trudy M Wassenaar; Florian Gunzer
Journal:  Gut Pathog       Date:  2015-06-19       Impact factor: 4.181

4.  Pathotypes and probiotics: response to a commentary on the detection of a Shiga toxin producing Escherichia coli in a Crohn's disease patient.

Authors:  Josias Rodrigues
Journal:  Gut Pathog       Date:  2015-07-11       Impact factor: 4.181

5.  Therapy of solid tumors using probiotic Symbioflor-2: restraints and potential.

Authors:  Dino Kocijancic; Sebastian Felgner; Michael Frahm; Ronja-Melinda Komoll; Aida Iljazovic; Vinay Pawar; Manfred Rohde; Ulrike Heise; Kurt Zimmermann; Florian Gunzer; Juliane Hammer; Katja Crull; Sara Leschner; Siegfried Weiss
Journal:  Oncotarget       Date:  2016-04-19

Review 6.  A Review of Research Conducted with Probiotic E. coli Marketed as Symbioflor.

Authors:  Claudia Beimfohr
Journal:  Int J Bacteriol       Date:  2016-11-22

7.  Therapeutic benefit of Salmonella attributed to LPS and TNF-α is exhaustible and dictated by tumor susceptibility.

Authors:  Dino Kocijancic; Sara Leschner; Sebastian Felgner; Ronja-Melinda Komoll; Michael Frahm; Vinay Pawar; Siegfried Weiss
Journal:  Oncotarget       Date:  2017-05-30

Review 8.  Insights from 100 Years of Research with Probiotic E. Coli.

Authors:  Trudy M Wassenaar
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2016-09-29

9.  Symbioflor2® Escherichia coli Genotypes Enhance Ileal and Colonic Gene Expression Associated with Mucosal Defense in Gnotobiotic Mice.

Authors:  Unai Escribano-Vazquez; Claudia Beimfohr; Deborah Bellet; Muriel Thomas; Kurt Zimmermann; Philippe Langella; Claire Cherbuy
Journal:  Microorganisms       Date:  2020-04-03

10.  Evaluating the Safety of Potential Probiotic Enterococcus durans KLDS6.0930 Using Whole Genome Sequencing and Oral Toxicity Study.

Authors:  Bailiang Li; Meng Zhan; Smith E Evivie; Da Jin; Li Zhao; Sathi Chowdhury; Shuvan K Sarker; Guicheng Huo; Fei Liu
Journal:  Front Microbiol       Date:  2018-08-21       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.